Behavioral effects of 5-HT(2C) receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

Experimental Neurology

Volumn 151, Issue 1, 1998, Pages 35-49

  Fox, Susan H ^a   Moser, Bill ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 HT(2C) receptor; Kynurenate; Parkinson's disease; Substantia nigra pars reticulata

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENSERAZIDE; DEXTRAN; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG VEHICLE; KYNURENIC ACID; LEVODOPA METHYL ESTER; MACROGOL; OXIDOPAMINE; POLIDOCANOL; QUINPIROLE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; GLOBUS PALLIDUS; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0032080242     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6792     Document Type: Article

References (39)

1. Albin R. L., Young A. B., Penney J. B. The functional anatomy of basal ganglia disorders. TINS. 12:1989;366-375.
2. Barone P., Morelli M., Popoli M., Cicarelli G., Campanella G., Di Chiara G. Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation. Neuroscience. 61:1994;867-873.
3. Brotchie J. M., McGuire S. G., Mitchell I. J., Crossman A. R. Alleviation of akinesia by intracerebral injections of EAA antagonists in the 6-OHDA model of parkinsonism. Neurosci. Lett. 38:1990;S76.
4. Brotchie J. M., Mitchell I. J., Sambrook M. A., Crossman A. R. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disord. 6:1991;133-138.
5. Brotchie, J. M. A. R. Crossman, I. J. Mitchell, S. Duty, C. Carroll, A. Cooper, B. Henry, N. Hughes, Y. Maneuf, 1993, Chemical signalling in the globus pallidus in parkinsonism, Progress in Brain Research, 99, 125, 139, Elsevier, Amsterdam.
6. Deniau J. M., Chevalier G. The lamellar organisation of the rat substantia nigra pars reticulata: distribution of projection neurons. Neuroscience. 46:1992;361-377.
7. Dray A., Davies J., Oakley N. R., Tongroach P., Vellucci S. The dorsal and medial raphe projections to the substantia nigra in the rat: Electrophysiological, biochemical and behavioural observations. Brain Res. 151:1978;431-442.
8. 1C. J. Med. Chem. 36:1993;1104-1107.
9. 2C2B. J. Med. Chem. 38:1995;2524-2530.
10. Fox S. H., Brotchie J. M. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 301:1996;27-30.
11. Graham W. C., Robertson R. G., Sambrook M. A., Crossman A. R. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci. 47:1990;91-97.
12. Grofova I., Deniau J. M., Kitai S. T. Morphology of the substantia nigra pars reticulata projection neurons intracellularly labelled with HRP. J. Comp. Neurol. 208:1982;352-368.
13. 4. Br. J. Pharmacol. 109:1993;618-624.
14. 1C. Br. J. Pharmacol. 94:1988;137-147.
15. 2C/2B. Br. J. Pharmacol. 111:1994;797-802.
16. 2C2B. Br. J. Pharmacol. 117:1996;427-434.
17. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
18. 1C. Eur. J. Pharmacol. 245:1993;179-182.
19. Lozano A. M., Lang A. E., Galvez-Jimenez N., Miyasaki J., Duff J., Hutchinson W. D., Dostrovsky J. O. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet. 346:1995;1383-1387.
20. Maneuf Y. P., Mitchell I. J., Crossman A. R., Woodruff G. N., Brotchie J. M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Res. 683:1995;102-108.
21. Marsden C. D., Parkes J. D. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1:1976;292-296.
22. Mcgeorge A. J., Faull R. L. M. The organisation of the projection from the cerebral cortex to the striatum in the rat. Neuroscience. 29:1989;503-537.
23. Mengod G., Ngyuyen H., Le H., Waeber C., Lubbert H., Palacios J. M. The distribution and cellular localisation of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridisation histochemistry: Comparison with receptor binding distribution. Neuroscience. 35:1990;577-591.
24. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., Crossman A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32:1989;213-226.
25. Nutt J. G. Levodopa-induced dyskinesias. Neurology. 40:1990;340-345.
26. Papa S. M., Engber T. M., Kask A. M., Chase T. N. Motor fluctuations in levodopa treated parkinsonian rats relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
27. Paxinos G., Watson C. The Rat Brain Stereotaxic Atlas. 1996;Academic Press, Sydney.
28. Pazos A., Probst A., Palacios J. M. Serotonin receptors in the human brain-III: Autoradiographic mapping of serotonin-1 receptors. Neuroscience. 21:1987;97-122.
29. Perkins M. N., Stone T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247:1982;184-187.
30. 2. Neuroscience. 79:1997;79-93.
31. Pollack P., Benabid A. L., Limousin P., Benazzouz A., Hoffmann D., Le Bas J. F., Perret J. Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Adv. Neurol. 69:1996;591-594.
32. Pycock C. J. Turning behaviour in animals. Neuroscience. 5:1980;461-514.
33. Radja F., Descarries L., Dewar K. M., Reader T. A. Serotonin 5HT1 and 5HT2 receptors in adult rat brain after destruction of nigrostriatal dopamine neurons: A quantitative autoradiographic study. Brain Res. 606:1993;273-285.
34. 2c. Neuroscience. 69:1995;903-913.
35. Robledo P., Feger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: Electrophysiological data. Brain Res. 518:1990;47-54.
36. St-Pierre J. A., Bedard P. J. Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model. Brain Res. 660:1994;255-260.
37. Weick B. G., Walters J. R. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Brain Res. 405:1987;234-246.
38. Wouterlood F. G., Jorritsma-Byham B. The anterograde neuroanatomical tracer biotinylated dextran-amine: comparison with the tracerphaeolus vulgaris-. J. Neurosci. Methods. 48:1993;75-83.
39. Zhou F. C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine lesion in the substantia nigra of adult rat brain. Brain. Res. 556:1991;108-116.